Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of etanercept

References

1. Rosas J, Llinares-Tello F, de la Torre I, Santos-Ramírez C, Senabre-Gallego JM, Valor L, et al. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice. Clin Exp Rheumatol 2014;32:942–8.Search in Google Scholar

2. Zandvliet ML, van Bezooijen JS, Bos MA, Prens EP, van Doorn M, Bijen I, et al. Monitoring antigen-specific biologics: current knowledge and future prospects. Ther Drug Monit 2013;35:588–94.10.1097/FTD.0b013e318295f6b2Search in Google Scholar PubMed

3. Llinares-Tello F, Rosas-Gómez de Salazar J, Senabre-Gallego JM, Santos-Soler G, Santos-Ramírez C, Salas-Heredia E, et al. Practical application of acid dissociation in monitoring patients treated with adalimumab. Rheumatol Int 2014;34:1701–8.10.1007/s00296-014-3032-0Search in Google Scholar PubMed

4. Llinares Tello F, Rosas Gómez de Salazar J, Senabre Gallego JM, Santos Soler G, Santos Ramírez C, Salas Heredia E, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50:1845–7.10.1515/cclm-2012-0050Search in Google Scholar PubMed

5. Valor L, Hernández Flórez D, de la Torre I, Llinares F, Rosas J, Yagüe J, et al. Infliximab and adalimumab levels and antidrug antibodies detection in patients with rheumatoid arthritis: an interlaboratory comparison using a commercial ELISA assay. Ann Rheum Dis 2014;73(Suppl 2):937.10.1136/annrheumdis-2014-eular.3290Search in Google Scholar

6. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765–71.10.1111/apt.12030Search in Google Scholar PubMed

7. Rispens T, van der Kleij D. Reply to Ruiz-Argüello et al.: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:e291–2.10.1515/cclm-2013-0570Search in Google Scholar PubMed

8. Ruiz-Argüello B, Ruiz del Agua A, Torres N, Monasterio A, Martínez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 2013;51:e287–9.10.1515/cclm-2013-0461Search in Google Scholar PubMed

9. Kneepens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 2014. [Epub ahead of print 7 May, 2014]. doi:10.1136/annrheumdis-2014-205213.10.1136/annrheumdis-2014-205213Search in Google Scholar PubMed

10. Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88–91.10.1136/annrheumdis-2011-200184Search in Google Scholar PubMed